Tag: VTE

Inari Medical appoints pulmonologist Victor F Tapson as VP of Medical...

Inari Medical has announced that the company has appointed Victor F Tapson as vice president of Medical Affairs. Tapson has devoted his medical career to...

Thromboprophylaxis with anticoagulants “likely effective” at preventing VTE post-vascular surgery, larger...

“Among patients undergoing vascular surgery, thromboprophylaxis with anticoagulants showed a trend towards reduced incidence of VTE when compared to placebo,” Tarek Haykal (Duke...

Global surgery study finds recent or current COVID-19 infection linked to...

New research published in Anaesthesia (a journal of the Association of Anaesthetists) shows that venous thromboembolisms (VTEs) are 50% more likely to occur in patients...

CHEST releases new guidelines for antithrombotic therapy for VTE disease

The American College of Chest Physicians (CHEST) recently released new clinical guidelines for venous thromboembolism (VTE) management, “Antithrombotic therapy for VTE disease: Second update...
reduced hospital time and costs Xarelto

Janssen submits new drug application to US FDA for Xarelto (rivaroxaban)...

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced it has submitted a new drug application (NDA) to the US Food and Drug...
kirill lobastov

Adjunctive compression to standard prophylaxis for postoperative VTE shows benefit in...

Among patients with a Caprini score of ≥11 who received standard prophylaxis for venous thromboembolism (VTE), adjunctive intermittent pneumatic compression (IPC) resulted in a...
cancer patient

Mayo Clinic study provides clarity on use of anticoagulants to treat...

A study by Mayo Clinic researchers provides some clarity on the use of direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, to treat...

Study launched to assess blood clot prediction model for paediatric patients

Monroe Carell Jr Children's Hospital at Vanderbilt (Nashville, USA) has launched a study to determine the impact of a predictive model for identifying paediatric...

Recent advances in VTE management provide much-needed clarity, but more needs...

Manjit Gohel (Cambridge, UK) and Stephen Black (London, UK) write that several recent advances in the management of venous thromboembolism (VTE) have provided clarity...

Further research will soon generate standardised approach to VTE in COVID-19...

At VENOUS2021 (17–20 March, virtual), the annual meeting of the American Venous Forum, Geno Merli (Thomas Jefferson University Hospital, Philadelphia, USA) gave a keynote...

What an interventionalist needs to know about DOACs in 2021

The publication of positive new data and a need to minimise hospital visits during the COVID-19 pandemic has seen a general trend towards using...

Towards universal adoption: Development of the AVF and SVS EHIT guidelines

While various treatment regimens for the “unique complication” of endothermal heat-induced thrombosis (EHIT) following endovenous ablation have been developed, Lowell S Kabnick tells Venous...

Interview: Comprehensive, patient-friendly risk assessment “crucial” to VTE prevention

From the first research linking heparin to a reduction in fatal pulmonary embolism (PE), to the development and refinement of risk assessment tools to...
geko OnPulse

Marathon Medical wins inclusion of the Geko device on its Veterans...

Sky Medical Technology has announced the inclusion of its flagship product, the Geko device, on a US Veterans Health Administration (VA) Federal Supply Schedule...

Joseph Caprini receives first CX Venous Lifetime Achievement Award, as speakers...

As evolving treatment modalities offer the potential for improved outcomes in patients with deep venous disease, the importance of patient selection and the need...
cancer patient

High thrombotic risk in cancer patients receiving immunotherapy

According to a recent study, patients with cancer under immune checkpoint inhibitor therapy are at high risk of thromboembolism, especially venous thromboembolism (VTE). Furthermore,...
reduced hospital time and costs Xarelto

Bayer receives approval in the UK for Xarelto to treat and...

Bayer has received approval in the UK for the use of its oral Factor Xa inhibitor Xarelto (rivaroxaban) to treat venous thromboembolism (VTE) and...

VTE management in COVID-19: “Use evidence-based prophylaxis and enrol patients in...

Venous thromboembolism (VTE) in COVID-19 patients was a key topic on the agenda of The VEINS (Venous Endovascular INterventional Strategies) session at VIVA 2020...

A multidisciplinary approach to VTE in COVID-19 patients is warranted

The nature of venous thromboembolism (VTE) in COVID-19 patients is complex, and treatment strategies regarding drug type and dosing continue to evolve, writes Sanjum...

DIVERSITY trial finds adjusted dabigatran dosing algorithm appropriate for treatment of...

In a recent randomised controlled trial, an age-adjusted, weight-adjusted dabigatran dosing algorithm was found to be appropriate in children under 18 years old with...
cancer patient

Comparable risk of recurrent VTE between patients with unprovoked VTE and...

Patients with venous thromboembolism (VTE) carry a high risk of recurrence. Accordingly, a 16-year Danish prospective cohort study of nearly 74,000 patients with incident VTE...

Society of Interventional Radiology publishes IVC filter guidelines

The Society of Interventional Radiology (SIR) recently published new clinical practice guidelines that provide evidence-based recommendations on the use of inferior vena cava (IVC)...
cancer patient

DOACs show promise over heparin injections in meta-analysis comparing cancer-associated VTE...

A recent meta-analysis found that direct oral anticoagulants (DOACs) appear to be a “reasonable alternative” to low molecular weight heparin (LMWH) for the treatment...

COVID-19 associated VTE: International thrombosis community urge WHO to act

The International Society on Thrombosis and Haemostasis (ISTH), on behalf of the international thrombosis community, have called on the World Health Organisation (WHO) to...
Olivia S Costa

Rivaroxaban associated with reduced risk of recurrent VTE versus warfarin in...

In a study evaluating rivaroxaban (Xarelto; Bayer) versus warfarin for the treatment and prevention of recurrent venous thromboembolism (VTE) in patients with obesity, results...

Study reports low rates of bleeding and VTE after 12 months...

Daiichi Sankyo Europe GmbH has announced results from five analyses of 12-month data from ETNA-VTE (Edoxaban treatment in routine clinical practice in patients with...

AHA and ISTH release joint statement on future VTE research priorities

The International Society on Thrombosis and Haemostasis (ISTH) and the American Heart Association (AHA) have released a joint scientific statement identifying the top five priorities for...

American Heart Association issues call to action to prevent VTE in...

Venous thromboembolism (VTE) is the leading cause of preventable hospital death in the USA and worldwide. A new policy statement by the American Heart...
geko OnPulse

Geko device represents an alternative to IPC devices during COVID-19

Sky Medical Technology highlights a publication on 5 May 2020 in the Journal of Thrombosis and Haemostasis showing the incidence of venous thromboembolism (VTE) in...
compression

Compression stockings might not be needed to prevent blood clots after...

Compression stockings might be unnecessary to prevent blood clots in most patients undergoing non-emergency (elective) surgery, finds a clinical trial published by The BMJ...
COVID-19

New study addresses thromboembolic complications in COVID-19 patients

There is an “urgent need” to improve specific venous thromboembolism (VTE) diagnostic strategies and investigate the efficacy and safety of thromboprophylaxis in ambulatory COVID-19...

AVF releases white paper on considerations in prophylaxis and treatment of...

The COVID-19 subcommittee of the American Venous Forum (AVF) has issued a white paper on considerations in prophylaxis and treatment of venous thromboembolism (VTE)...
Human colorectal cancer cells

Virtual ACC: Caravaggio study confirms noninferiority of apixaban to heparin for...

It has been found that oral apixaban is noninferior to subcutaneous dalteparin for the treatment of cancer-related venous thromboembolism (VTE), as revealed by Giancarlo...
Nadia Rosencher

Virtual ACC: Rivaroxaban demonstrates superiority over enoxaparin for prevention of VTE...

Results of PRONOMOS, a randomised, controlled, noninferiority trial, have shown rivaroxaban to be more effective than enoxaparin in the prevention of major venous thromboembolic...
Venous News for specialists

New prediction tool for patients at risk of venous thromboembolism validated

Investigators in The Netherlands, France and Belgium have developed a risk assessment model for venous thromboembolism (VTE). Published by The Lancet in EClinicalMedicine, the...
Thrombolex bashir

FDA approval granted to Thrombolex for Bashir Endovascular Catheter-Short Basket

  Thrombolex has announced that the company has received US Food and Drug Administration (FDA) clearance for the Bashir Endovascular Catheter - Short Basket (BEC...
Geko Device

FDA approval granted to calf stimulation device for patients at high...

UK-based Sky Medical Technology has received US Food and Drug Administration (FDA) 510(k) clearance for its "geko" device for stimulation of the calf muscles...
risk of recurrent VTE in morbidly obese patients with XARELTO

New research reveals decreased risk of recurrent VTE in morbidly obese...

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the publication of new real-world evidence which confirms that XARELTO (rivaroxaban) reduces the risk...
how is lower levels of serum bilirubin and venous thromboembolism related

Study finds significant association between low bilirubin levels and venous thromboembolism

A recent paper published by Hakan Duman (Recep Tayyip Erdoğan University, Rize, Turkey) and colleagues in the Journal of Vascular Surgery: Venous and Lymphatic...

Edoxaban emerges as alternative to dalteparin for cancer-associated VTE

A new analysis has identified patient populations with cancer-associated venous thromboembolism (VTE) who could benefit from treatment with oral anticoagulant edoxaban, taken once daily. Daiichi...

Study reports two- to threefold reduction of varicose veins in pregnant...

A new randomised controlled trial evaluated the preventative effect of compression stockings during pregnancy on the incidence of varicose veins as well as venous...
reduced hospital time and costs Xarelto

FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...

Cancer-associated VTE trial sees “lower rate of recurrent VTE with edoxaban...

Daiichi Sanyoko has announced the results from their Hokusai-VTE CANCER trial evaluating the direct oral anticoagulant edoxaban for treatment of venous thromboembolism (VTE) in...

FDA approves new 10mg dosing for rivaroxaban to reduce continued risk...

Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous...
Venous News for specialists

GARFIELD-VTE Registry sheds light on global heterogeneity of venous thromboembolism patients,...

The first results from the GARFIELD-VTE (Global anticoagulant registry in the field—venous thromboembolism) were presented at the International Society on Thrombosis and Haemostasis Congress...

FDA grants priority review of Xarelto for a 10mg dose to...

The US Food and Drug Administration (FDA) has accepted, for priority review, a supplemental new drug application (sNDA) for Janssen’s Xarelto (rivaroxaban), to include...